Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

External Validation of Radiation-Induced Dyspnea Models on Esophageal Cancer Radiotherapy Patients.

Shi Z, Foley KG, Pablo de Mey J, Spezi E, Whybra P, Crosby T, van Soest J, Dekker A, Wee L.

Front Oncol. 2019 Dec 16;9:1411. doi: 10.3389/fonc.2019.01411. eCollection 2019.

2.

Effect of Changing Diet on Gastric Ulceration in Exercising Horses and Ponies After Cessation of Omeprazole Treatment.

Luthersson N, Bolger C, Fores P, Barfoot C, Nelson S, Parkin T, Harris P.

J Equine Vet Sci. 2019 Dec;83:102742. doi: 10.1016/j.jevs.2019.05.007. Epub 2019 May 14.

PMID:
31791527
3.

Discovery of stable and prognostic CT-based radiomic features independent of contrast administration and dimensionality in oesophageal cancer.

Piazzese C, Foley K, Whybra P, Hurt C, Crosby T, Spezi E.

PLoS One. 2019 Nov 22;14(11):e0225550. doi: 10.1371/journal.pone.0225550. eCollection 2019.

4.

Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.

Wills L, Maggs R, Lewis G, Jones G, Nixon L, Staffurth J, Crosby T; SCOPE 1 trial management group and collaborators.

Radiat Oncol. 2017 Nov 15;12(1):179. doi: 10.1186/s13014-017-0916-7.

5.

The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.

Cox S, Hurt C, Grenader T, Mukherjee S, Bridgewater J, Crosby T.

Radiother Oncol. 2017 Oct;125(1):154-159. doi: 10.1016/j.radonc.2017.08.023. Epub 2017 Sep 8.

6.

Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1.

Cox S, Powell C, Carter B, Hurt C, Mukherjee S, Crosby TD.

Br J Cancer. 2016 Jul 12;115(2):172-7. doi: 10.1038/bjc.2016.129. Epub 2016 Jun 21.

7.

Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer.

Warren S, Partridge M, Carrington R, Hurt C, Crosby T, Hawkins MA.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):423-9. doi: 10.1016/j.ijrobp.2014.06.028.

8.

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G.

Lancet Oncol. 2013 Jun;14(7):627-37. doi: 10.1016/S1470-2045(13)70136-0. Epub 2013 Apr 25.

9.

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus.

Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD.

BMC Cancer. 2011 Oct 28;11:466. doi: 10.1186/1471-2407-11-466.

Supplemental Content

Loading ...
Support Center